Horizon Pharma acquires pharmaceuticals for $ 1.1 billion

Horizon Pharma announced the acquisition of Hyperion Therapeutics for $ 1.1 billion. The pharmacist offered $ 46 per share, an increase of 7.6% over the closing value of the shares of Hyperion.
According to the Wall Street Journal, the deal will contribute $ 100 million to Ebitda of Horizon in 2016, and $ 50 million in cost cuts.
The acquisition will include two treatments for rare conditions the Horizon's portfolio. The two drugs, Ravicti and Buphenyl, brought $ $144,4 million in sales last year.
The deal will also expand the infrastructure for "orphan" diseases, according to the President of Horizon, Timothy p. Joseph. Orphan diseases are rare conditions, in which pharmaceutical companies usually don't invest.
The transaction was accepted by both companies and must be terminated at the end of the second quarter.
In September, Horizon moved its headquarters to Dublin, Ireland, to reduce tax payments. This change enabled the purchase of Irish Vidara Therapeutics International, for $ 587 million.